This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This week we will feature two studies involving venetoclax, which were shared at ASH 2020.
Here is an intriguing question: If venetoclax has already worked once, will it work a second time around? Venetoclax is often only used as a fixed duration therapy, which means it is stopped after either a predetermined number of months or when the patient reaches uMRD. However, not everyone achieves a state of complete remission, and if they do, not everyone stays in complete remission. This leads to the question of what therapy should be tried next. During ASH 2020, Dr. Meghan Thompson presented a retrospective study in which 25 heavily pre-treated patients for whom venetoclax (alone or in combination) worked the first time around, were retreated with venetoclax after relapse. What was the response rate the second time around? Find out here!
During ASH 2020, Steve Bloom, CLL Society’s President and Chair of the Board of Directors, interviewed Dr. Jennifer Brown regarding a clinical trial in which a heavily pre-treated group of relapsed/refractory CLL patients are being treated with the PI3 kinase inhibitor duvelisib in combination with venetoclax. This ongoing trial is looking to see if there are higher response rates and deeper rates of uMRD from the drug combination. Of interest to some will be the addition of a Richter’s Transformation cohort to this trial. Perhaps the most exciting part of this video comes near the end when Dr. Brown mentions that multiple strategies in other trials are putting a wide range of drug classes to the test in targeting Richter’s Transformation. Learn more here!
Join us on Friday, March 26th (11:00 AM PT, 12:00 PM MT, 1:00 PM CT, and 2:00 PM ET) for CLL Society’s COVID-19 Virtual Community Meeting: Contagion, Variants, and Vaccines. The global COVID-19 pandemic continues to rage in 2021 as vaccination distribution begins. CLL experts Drs. Steve Rosen and Alexey Danilov, infectious disease physician Dr. Sanjeet Dadwal, lab scientist Dr. Susan Leclair, and CLL Society’s own Dr. Brian Koffman will bring you the most up-to-date information. It is critical that CLL patients and their caregivers receive credible COVID-19 information from different expert voices. Our expert panelists will answer audience questions. Register here and submit your questions!
CAR-T Ed Forum: The Basic Science and Latest Data
Please join CLL Society for a two-hour event on Wednesday, April 21st (10:00 AM PT, 11:00 AM MT, 12:00 PM CT, and 1:00 PM ET) as we continue to strengthen your learning about CAR-T therapy. Dr. John Pagel’s presentation will kick us off. He will explain exactly what CAR-T therapy is, guide us through how it works, and share where this treatment is headed in the future. Dr. Tanya Siddiqi’s ongoing CAR-T clinical trial at the City of Hope National Medical Center is well known. She will present her most current data showing the success of CAR-T therapy in CLL, with and without ibrutinib. Dr. Larry & Sharon Saltzman will share their CLL CAR-T journey from both the doctor-turned-patient perspective, as well as the caregiver point of view. Learn more and register here!
2021 ASCO: Special Free Admission for Patients and Survivors
As our recent Ed Forum: ASH 2020 Comes to You highlighted, CLL Society encourages as much learning as possible from all major conferences where new CLL research is presented. The American Society of Clinical Oncology (ASCO) Annual Meeting will be held online June 4th-8th. This year, cancer patients and survivors are for the very first time able to register to attend the virtual meeting presentations at no cost! You may request a unique registration code by sending an email to email@example.com. Please note that unlike the ASH Annual Meeting, which is strictly devoted to hematology, ASCO is mostly about solid tumors. There may only be a few sessions that are specifically focused on CLL, most of which will be aimed at an audience of oncologists. Nonetheless, we realize many of our readers may find value and benefit from this unique new opportunity to attend ASCO. Find out more here.
Support Group Member Survey
Last call! More than 1,800 CLL patients and caregivers attend our 38 CLL-specific Support Groups, which hold meetings monthly via Zoom. If you take part in one of these groups, your feedback is important to us. If you have already completed our survey, thanks for your help! If not, please complete the Support Group Member survey here before the end of February.
Please Support CLL Society
CLL Society is the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
CLL Society Support Group meetings have moved to a virtual platform for most locations due to the threat of coronavirus. Support group members will receive an invitation to register for the meeting from the support group facilitator. If you are new to the group, please contact the RSVP email for the Support Group in your region. Once it is safe again, we will resume in-person meetings.
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.